Literature DB >> 25281237

Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.

Su Guan1, Chun-Yun Hu2, Meng-Ying He2, Ying-Ying Yang2, Yu-Xin Tang2, Jie-di Chen2, Li-Jie Huang2, Wen Tan3.   

Abstract

This study was to compare pharmacokinetics and bile transformation of R-enantiomer bambuterol with its racemate. Pharmacokinetics of R-enantiomer was investigated after single-dose intravenous and three doses of oral administration to rats and beagle dogs. To compare the pharmacokinetics with racemic bambuterol, the same oral doses of racemic bambuterol were also administrated; the blood and bile samples were collected by cannulation. A validated LC-MS/MS method was used to assess the level of bambuterol in plasma and bile. After single intravenous administration, no significant differences were observed between the two drugs in pharmacokinetic data. After oral dosing of R-bambuterol, the AUCs of R-enantiomer presented linear correlation. After same oral dosing of R-enantiomer and its racemate, all the pharmacokinetic parameters were equivalent. However, the clearance and apparent distribution had different results due to species and administration route difference. The bile transformation of these two compounds was similar and implicated that liver transformation accounted for the major metabolism of them. The bioavailability of R-enantiomer and racemate were comparative and relatively high in beagle dogs. Thus, R-enantiomer had a comparative pharmacokinetic profile and bile transformation with racemic bambuterol in rats and beagle dogs. These findings provided references for further clinical study.

Entities:  

Keywords:  Bambuterol; Beagle dogs; Pharmacokinetics; R-enantiomer; Rats

Mesh:

Substances:

Year:  2014        PMID: 25281237     DOI: 10.1007/s13318-014-0228-3

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  22 in total

1.  Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism.

Authors:  J K Ward; J Dow; N Dallow; P Eynott; S Milleri; G P Ventresca
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 2.  Beta-adrenoceptor agonists and asthma--100 years of development.

Authors:  Bertil Waldeck
Journal:  Eur J Pharmacol       Date:  2002-06-07       Impact factor: 4.432

3.  Prodrug research: futile or fertile?

Authors:  Bernard Testa
Journal:  Biochem Pharmacol       Date:  2004-12-01       Impact factor: 5.858

4.  Preparative HPLC separation of bambuterol enantiomers and stereoselective inhibition of human cholinesterases.

Authors:  Ivana Gazić; Anita Bosak; Goran Sinko; Vladimir Vinković; Zrinka Kovarik
Journal:  Anal Bioanal Chem       Date:  2006-07-25       Impact factor: 4.142

5.  Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood.

Authors:  A Tunek; L A Svensson
Journal:  Drug Metab Dispos       Date:  1988 Sep-Oct       Impact factor: 3.922

Review 6.  Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris?

Authors:  E R McFadden
Journal:  J Allergy Clin Immunol       Date:  1995-03       Impact factor: 10.793

7.  Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans.

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

8.  Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

Authors:  U K Walle; G R Pesola; T Walle
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

9.  Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma.

Authors:  D S Sitar; C P Warren; F Y Aoki
Journal:  Clin Pharmacol Ther       Date:  1992-09       Impact factor: 6.875

10.  One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients.

Authors:  G Persson; A Baas; A Knight; B Larsen; H Olsson
Journal:  Eur Respir J       Date:  1995-01       Impact factor: 16.671

View more
  1 in total

1.  Enantioselective Pharmacokinetics of Bambuterol in Preclinical Species: Does S-bambuterol Influence the Clearance of the R-antipode?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.